Emerging Role of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease—Insights from the 2022 ESC Guidelines
Authors:
- Marta BanaszkiewiczMBMarta Banaszkiewicz
- Paweł KurzynaPKPaweł Kurzyna
- Nina KubikowskaNKNina Kubikowska
- Magda MuchaMMMagda Mucha
- Aleksander RudnikARAleksander Rudnik
- Aleksandra GąseckaAleksandra Gąsecka
- Arkadiusz PietrasikAPArkadiusz Pietrasik
- Marcin GrabowskiMGMarcin Grabowski
- Miłosz J. JaguszewskiMJMiłosz J. Jaguszewski
- Piotr KasprzykPKPiotr Kasprzyk
- Piotr KędzierskiPKPiotr Kędzierski
- Dariusz CiećwierzDCDariusz Ciećwierz
Open Access
- 16 August 2023
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (16) , 5336
Abstract
In this article, we discuss the topic of chronic thromboembolic pulmonary disease (CTEPD) and the growing role of balloon pulmonary angioplasty (BPA) in its treatment. We present the pathophysiology of CTEPD which arises from an incomplete resolution of thrombi in the pulmonary arteries and leads to stenosis and occlusion of the vessels. The article focuses mainly on the chronic thromboembolic pulmonary hypertension (CTEPH) subpopulation for which prognosis is very poor when left untreated. We describe a multimodal approach to treating CTEPH, including pulmonary endarterectomy (PEA), BPA, and pharmacological therapies. Additionally, the benefits of pharmacological pre-treatment before BPA and the technical aspects of the procedure itself are outlined. It is emphasized that BPA does not replace PEA but serves as a complementary treatment option for eligible patients. We summarized efficacy and treatment goals including an improvement in functional and biochemical parameters before and after BPA. Patients who received pre-treatment with riociguat prior to BPA exhibited a notable reduction in the occurrence of less severe complications. However, elderly patients are still perceived as an especially vulnerable group. It is shown that the prognosis of patients undergoing BPA is similar to PEA in the first years after the procedure but the long-term prognosis of BPA still remains unclear. The 2022 ESC/ERS guidelines highlight the significant role of BPA in the multimodal treatment of CTEPH, emphasizing its effectiveness and recommending its consideration as a therapeutic option for patients with CTEPD, both with and without pulmonary hypertension. This review summarizes the available evidence for BPA, patient selection, procedural details, and prognosis and discusses the potential future role of BPA in the management of CTEPH.Keywords
Funding Information
- Centre of Postgraduate Medical Education (501-1-054-25-23)
This publication has 90 references indexed in Scilit:
- Percutaneous Transluminal Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary HypertensionCirculation: Cardiovascular Interventions, 2012
- Refined Balloon Pulmonary Angioplasty for Inoperable Patients with Chronic Thromboembolic Pulmonary HypertensionCirculation: Cardiovascular Interventions, 2012
- Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertensionEuropean Respiratory Journal, 2012
- Chronic Thromboembolic Pulmonary Hypertension (CTEPH)Circulation, 2011
- Bosentan for Treatment of Inoperable Chronic Thromboembolic Pulmonary HypertensionJACC, 2008
- Risk factors for chronic thromboembolic pulmonary hypertensionEuropean Respiratory Journal, 2008
- Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary HypertensionChest, 2008
- Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertensionEuropean Respiratory Journal, 2007
- Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary HypertensionThe Journal of Heart and Lung Transplantation, 2007
- Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertensionJournal of Thrombosis and Haemostasis, 2007